Impaired of Sexuality in Premenopausal Breast Cancer Patients  

作　　者：Paula Vendruscolo Tozatti Janete Vettorazzi Nathália Lobato Andrea Pires Souto Damin Paula Vendruscolo Tozatti;Janete Vettorazzi;Nathália Lobato;Andrea Pires Souto Damin(Postgraduate Program in Health Sciences: Gynecology and Obstetrics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brasil;Department of Gynecology and Obstetrics, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil;Service of Obstetrics and Gynecology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brasil;Nucleus of Studies and Research in Sexuality of Rio Grande do Sul (NEPESEX), CNPq, Porto Alegre, Brasil;Head of the Mastology Service of the Hospital de Clínicas de Porto Alegre, Porto Alegre, Brasil)

机构地区：[1]Postgraduate Program in Health Sciences: Gynecology and Obstetrics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brasil [2]Department of Gynecology and Obstetrics, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil [3]Service of Obstetrics and Gynecology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brasil [4]Nucleus of Studies and Research in Sexuality of Rio Grande do Sul (NEPESEX), CNPq, Porto Alegre, Brasil [5]Head of the Mastology Service of the Hospital de Clínicas de Porto Alegre, Porto Alegre, Brasil

出　　处：《Open Journal of Obstetrics and Gynecology》2021年第11期1596-1607,共12页妇产科期刊（英文）

摘　　要：<strong>Introduction:</strong><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">treatment modalities </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">for </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Breast cancer may impair the sexual function of women, especially in the pre-menopausal period. Treatment in this group of women has a huge impact in quality of life. The main objective of this study was to evaluate the prevalence of sexual dysfunction (SD) after treatment for breast cancer among women who were premenopausal at the diagnosis of neoplasia.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><b><span style="font-family:Verdana;">Material and Methods:</span></b></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> All women diagnosed with premenopausal breast cancer at one outpatient clinic from March 2019 to September 2020 were selected. Participants answered two sexual function questionnaires (the Female Sexual Function Index [FSFI-19] and Female Sexual Quotient [QS-F]) and a quality of life [QOL] questionnaire [EORTC QLQ-C30]). Sociodemographic and tumor characteristics were also studied.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><b><span style="font-family:Verdana;">Results:</span></b></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> Fifty-eight pre-menopausal wom<strong>Introduction:</strong><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">treatment modalities </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">for </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Breast cancer may impair the sexual function of women, especially in the pre-menopausal period. Treatment in this group of women has a huge impact in quality of life. The main objective of this study was to evaluate the prevalence of sexual dysfunction (SD) after treatment for breast cancer among women who were premenopausal at the diagnosis of neoplasia.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><b><span style="font-family:Verdana;">Material and Methods:</span></b></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> All women diagnosed with premenopausal breast cancer at one outpatient clinic from March 2019 to September 2020 were selected. Participants answered two sexual function questionnaires (the Female Sexual Function Index [FSFI-19] and Female Sexual Quotient [QS-F]) and a quality of life [QOL] questionnaire [EORTC QLQ-C30]). Sociodemographic and tumor characteristics were also studied.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><b><span style="font-family:Verdana;">Results:</span></b></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> Fifty-eight pre-menopausal wom

关 键 词：Breast Cancer SEXUALITY Quality of Life Sexual Dysfunction Premenopausal Period FSFI-19 QS-F EORTC QLQ-C30 

分 类 号：R73[医药卫生—肿瘤]